	US 12,440,488 B2
	Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
Norbert F. Voelkel, Denver, CO (US); Charles Magolske, Denver, CO (US); and Erik R. Eglite, Lake Forest, IL (US)
Assigned to ReversPAH LLC, Denver, CO (US)
Filed by ReversPAH LLC, Denver, CO (US)
Filed on Dec. 1, 2021, as Appl. No. 17/539,470.
Claims priority of provisional application 63/119,827, filed on Dec. 1, 2020.
Prior Publication US 2022/0168297 A1, Jun. 2, 2022
Int. Cl. A61K 31/495 (2006.01); A61K 9/00 (2006.01); A61K 31/137 (2006.01); A61K 31/167 (2006.01); A61K 31/381 (2006.01); A61K 31/5386 (2006.01); A61K 31/5575 (2006.01); A61K 31/5578 (2006.01); A61K 31/5585 (2006.01); A61K 31/573 (2006.01)

CPC A61K 31/495 (2013.01) [A61K 9/008 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/381 (2013.01); A61K 31/5386 (2013.01); A61K 31/5575 (2013.01); A61K 31/5578 (2013.01); A61K 31/5585 (2013.01); A61K 31/573 (2013.01)]

24 Claims

1. A method of treating COPD and inhibiting further lung damage development in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising: an effective amount of diethylcarbamazine-citrate DEC-citrate); an effective amount of a prostacyclin analogue selected from the group consisting of Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost; and a buffering agent, wherein the composition is an aerosol, comprises a propellant, or is in an inhalation delivery device, and wherein the pharmaceutical composition inhibits inflammatory cell infiltration when administered to the lungs.